Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal | MicrobiomeTrials← Back to trialsNCT05530759
Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
RecruitingOBSERVATIONAL
Trial Details
Start: 2022-06-29Est. Completion: 2031-04-30
Enrollment target: 50 participants Locations- Mayo Clinic in Rochester, Rochester, Minnesota, United States
Other microbiome trials you might be interested in
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMDSTransplantation, Stem CellConditioning TherapySHR2554Azacytidine
This study was designed as a prospective, multicenter, open-label, randomized controlled trial. Eligible participants we…
Suzhou, ChinaEst. completion Jun 2029
Malignancy, HematologicNeoplasms, Hematologic
Neoplasms, Hematopoietic
Blood Cancer
Hematological Neoplasms
Hematopoietic Malignancies
Dysmyelopoietic Syndromes
Hematopoetic Myelodysplasia
Myeloid Leukemia, Acute
Nonlymphoblastic Leukemia, Acute
Leukemia, Lymphocytic, Acute
Background:
Blood cancers (such as leukemias) can be hard to treat, especially if they have mutations in the TP53 or RA…
Bethesda, United StatesEst. completion Apr 30, 2029
Constitutional Mismatch Repair Deficiency SyndromeHematopoietic and Lymphoid Cell NeoplasmLynch SyndromeRecurrent LymphomaRecurrent Malignant Solid NeoplasmRecurrent NeuroblastomaRecurrent Primary Central Nervous System NeoplasmRefractory LymphomaRefractory Malignant Solid NeoplasmRefractory NeuroblastomaRefractory Primary Central Nervous System NeoplasmXeroderma Pigmentosum
This phase Ib trial investigates the side effects of the combination of nivolumab and ipilimumab, and to see how well th…
Palo Alto, United StatesCompleted Jun 21, 2022